

Development of a Modified Hand Mobility in Scleroderma (HAMIS) Test and its Potential as an Outcome Measure in Systemic Sclerosis

Gunnel Sandqvist, Jan-Åke Nilsson, Dirk M. Wuttge, and Roger Hesselstrand

ABSTRACT. Objective. To modify the hand mobility in scleroderma (HAMIS) test by reducing the number of items and amount of equipment needed, and to evaluate the construct validity of this modified HAMIS (mHAMIS).

Methods. Our retrospective study is based on 266 patients previously examined using the original HAMIS test. Data were divided into 3 groups depending on disease duration after onset: (1) 0–3 years, (2) 3.1–5 years, and (3) 5.1–9 years. Disease variables included were skin involvement using the disease subset and the modified Rodnan skin score (mRSS), and digital lesions. Cronbach's alpha coefficient was calculated separately for limited (lcSSc) and diffuse systemic sclerosis (dcSSc) for the right and left hand, and for the groups with different disease duration. The construct validity of the mHAMIS was assessed by searching for a correlation with hand skin score.

Results. An mHAMIS test consisting of finger flexion, finger extension, finger abduction, and dorsal extension was developed. The internal consistency of this test was 0.78, 0.83, and 0.73 in the 3 groups with different disease duration. In the whole study group, mHAMIS showed a significant correlation with mRSS and hand skin score ($r_s = 0.39$ and 0.43 , respectively), and was able to discriminate between lcSSc and dcSSc ($p = 0.001$), and between patients with and without ulcers ($p = 0.015$).

Conclusion. The mHAMIS involves 4 easily measurable items and has the potential to be a relevant clinical measure of outcome in the evaluation of fibrotic skin involvement in SSc. (First Release Oct 1 2014; J Rheumatol 2014;41:2186–92; doi:10.3899/jrheum.140286)

Key Indexing Terms:

SYSTEMIC SCLEROSIS

HAND MOBILITY IN SCLERODERMA

MODIFIED HAND MOBILITY IN SCLERODERMA

Systemic sclerosis (SSc; scleroderma) is an autoimmune disease characterized by microvascular injury and excessive fibrosis of the skin and internal organs¹. Although there is considerable individual variation, skin involvement tends to reach a maximum within the first 3 years², after which the skin becomes thinner, although complete remission in the fingers and hands is less common³. Skin thickening is a manifest consequence of SSc. Skin thickness is determined by using the modified Rodnan skin score (mRSS)⁴, the most commonly used and valid method of assessing skin involvement in SSc, and meets the requirements of an outcome measure according to the Outcome Measures in

Rheumatology Clinical Trials (OMERACT) filter. However, the mRSS provides a measure of the skin involvement of the whole surface of the body, and not specifically the hands. The hands account for only a small fraction of the total skin area of the body, but are necessary for many important functions in daily life. It is, therefore, important to study hand involvement separately, especially in studies on the outcome of therapy.

Hand involvement in SSc includes skin thickening, presumably caused by inflammatory edema and fibrosis, as well as vascular injury and articular involvement. Individuals may perceive impairment in mobility, hand strength, and dexterity, having a significant influence on the activities of daily living^{5,6,7,8,9}. Hand involvement is one of the early signs of the disease, and there is thus a need for tests that can provide information on the efficacy of therapeutic interventions aimed at minimizing functional impairment. In addition, there is a need for feasible endpoints in routine followup and clinical trials. The guidelines of the OMERACT filter¹⁰, and a combination of measures including body function, body structures, and activity and participation according to the different domains of the International Classification of Functioning (ICF)¹¹ are useful tools in the selection of appropriate outcome

From the Section of Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Supported by unrestricted grants from the Swedish Medical Research Council, the Medical Faculty of Lund University, the Swedish Rheumatism Association, the Norrbacka-Eugenia Fund, King Gustaf V's 80-Year Fund, the Österlund Foundation, and the Kock Foundation.

G. Sandqvist, Reg OT, PhD; J-Å. Nilsson, BSc; D.M. Wuttge, MD, PhD; R. Hesselstrand, MD, PhD, G, Section of Rheumatology, Department of Clinical Sciences, Lund University.

Address correspondence to Dr. G. Sandqvist, Section of Rheumatology, Department of Clinical Sciences, Lund University, SE-221 85 Lund, Sweden. E-mail: gunnel.sandqvist@med.lu.se

Accepted for publication July 24, 2014.

measures. The Cochin Hand Function Scale (CHFS)¹² is a self-reported disability questionnaire that provides a reliable and valid measure within the activity domain, with significant correlations with activities of daily living in SSc^{13,14}. On the body function level, the performance-based Arthritis Hand Function Test (AHFT), measuring hand strength and dexterity¹⁵, and the Hand Mobility in Scleroderma (HAMIS) test¹⁶, measuring hand mobility, have been used in the assessment of hand function in SSc^{16,17}. The AHFT measures different aspects of hand function, and has shown significant correlations with the performance of activities of daily living, but not with skin involvement¹⁷.

The HAMIS test focuses on the mobility of the fingers and wrist, and comprises 9 items using differently sized grips and different movements¹⁶. The HAMIS test usually takes 10 min to perform in a patient with SSc. Advantages of the HAMIS test are the feasibility, the high interobserver and intraobserver reliability ($k_w = 0.82$ and 0.74 , respectively)¹³, and the test-retest reliability ($ICC = 0.99$)⁷. Further, the test has shown significant correlations with skin involvement in the hands in both cross-sectional and longitudinal followup studies, and with activities of daily living^{7,9,18,19}. HAMIS has also been shown to be sensitive to change, and to be a useful outcome measure in hand rehabilitation^{20,21}.

The HAMIS test clearly reflects the consequences of skin involvement on hand function. The test is not particularly time-consuming, but requires some equipment, which may be one reason why the test has not been used in clinical trials. To improve the feasibility of the HAMIS test in clinical trials, and to investigate its ability to measure the consequences of the fibrotic involvement of the hands, we decided to reevaluate the HAMIS test. The aims of our present study were thus to modify the original HAMIS test by reducing the number of items and the equipment needed (to provide a more feasible test for clinical trials), and to evaluate its construct validity in patients with different durations of SSc.

MATERIALS AND METHODS

Study design. Our retrospective cross-sectional study was conducted at 1 rheumatology department at a single center, and was based on measurements made with the HAMIS test between 1998 and 2011. Four experienced occupational therapists performed the assessments during this period. To elucidate possible differences during the edematous, indurative, and atrophic phases of the skin disease, the data were divided into 3 groups based on the date of assessment in relation to the duration of the disease: group (1) 0–3 years, (2) 3.1–5 years, and (3) 5.1–9 years after disease onset. Because the same patient may have been assessed during more of these periods, and may also have been assessed more than once in the same period, the patient's first assessment in each period was used to avoid possible duplication of data.

Ethical considerations. Our study was conducted in accordance with the Declaration of Helsinki and was approved by the Regional Ethics Committee in Lund. The patients were given verbal information on the aim of our study, and written consent was obtained according to the Declaration of Helsinki.

Subjects. All patients who were assessed twice or more during the period between 1998 and 2011, within the context of our regular followup program, and who fulfilled the American College of Rheumatology criteria for SSc²² were included. Two hundred sixty-six patients were included: 218 with limited cutaneous SSc (lcSSc) and 48 with diffuse cutaneous SSc (dcSSc). Disease onset was defined as the time of the first non-Raynaud manifestation. The relevant clinical characteristics of the patients participating in our study are presented in Table 1.

Instruments. The patient's skin involvement was characterized by subdivision into lcSSc or dcSSc, the measurement of the mRSS total skin score based on palpation of 17 anatomic sites⁴, and a subscore measuring skin involvement on the fingers, the hands, and the forearms (here referred to as the hand skin score). Digital vascular lesions were defined as the presence or absence of digital tip ulceration or pitting scars. Hand mobility was assessed with the HAMIS test. Both hands were assessed separately, giving a score of 0 to 27 for each hand¹⁶. Objective disease variables were assessed within the context of our regular followup program.

Statistical analysis. Clinical data are presented as the median and interquartile range (IQR), and as numbers and percentages. Cronbach's alpha coefficient was used to estimate the internal consistency of the HAMIS test in the different groups. According to Bland and Altman²³, α values of 0.7 to 0.8 are considered acceptable for scales that are used to compare groups in research studies. To estimate the construct validity of modified HAMIS (mHAMIS), and the degree to which mHAMIS and the skin score are related, the convergent validity of the mHAMIS test was assessed by searching for a correlation with the hand skin score. Moderate to high correlations were expected, and r_s values were interpreted as follows: $r_s \leq 0.25$ as little or no correlation, $r_s = 0.26$ – 0.49 as low correlation, $r_s = 0.50$ – 0.69 as moderate, $r_s = 0.70$ – 0.89 as high, and $r_s = 0.90$ – 1.00 as very high correlation²⁴.

The Mann-Whitney U test was used to assess the ability of the mHAMIS test to discriminate between the presence or not of ulcers or pitting scars, and between lcSSc and dcSSc.

RESULTS

Hand mobility and skin involvement in groups with different disease duration. Of the total number of 266 patients, 109 patients were categorized in Group 1 (0–3 yrs of disease duration), 118 in Group 2 (3.1–5 yrs of duration), and 143 in Group 3 (5.1–9 yrs of duration). All groups consisted mainly of women with lcSSc (Table 1). Hand mobility was 1 unit more impaired in the right hand in all groups ($p = 0.001$). The median HAMIS score in Group 1 was 7 points (4 points in the right hand and 3 points in the left), and 6 points in both Groups 2 and 3 (3 points in both the right and left hands in Group 2, and 3 points in the right hand and 2 points in the left hand in Group 3). Finger flexion, finger extension, and thumb abduction were more impaired in the right hand in all groups ($p < 0.05$). In Group 1, the skin scores for the fingers and the hands were higher on the right hand than on the left hand ($p = 0.004$ and $p = 0.035$, respectively). The distribution of the HAMIS scores in the 3 groups shows that finger flexion and extension were the most impaired functions in all groups, while pronation was impaired in only about 10% of the patients (Figure 1).

Development of the mHAMIS test based on groups with different disease durations. Cronbach's alpha coefficient with item reduction was calculated for the right and left hands separately for each group. Because of the high

Table 1. Clinical characteristics of the patients according to duration of SSc.

Characteristics	Group 1, 0–3 Yrs, n = 109	Group 2, 3.1–5 Yrs, n = 118	Group 3, 5.1–9 Yrs, n = 143
Female, n (%)	86 (79)	94 (80)	120 (84)
lcSSc, n (%)	87 (80)	99 (84)	120 (84)
Ulcers, n (%)	13/109 (12)	12/108 (11)	13/131 (10)
Pitting scars, n (%)	36/108 (33)	47/110 (43)	52/134 (39)
Age, median (IQR)	54 (47–65)	55.5 (46–64)	55 (47–64)
mRSS, median (IQR)	9 (4–16.1), n = 106	6 (3.5–12), n = 113	6 (3–9), n = 133
Hand skin score, median (IQR)	6 (4–10), n = 104	6.0 (2–8), n = 116	5 (2–7), n = 129
HAMIS score, median (IQR)	7 (3.5–13.5)	6 (2–12)	6 (3–9)

SSc: systemic sclerosis; lcSSc: limited cutaneous SSc; mRSS: modified Rodnan skin score; HAMIS: hand mobility in scleroderma; IQR: interquartile range.

proportion of individuals with lcSSc in each group, and the possible difference in skin involvement on the hands between lcSSc and dcSSc, Cronbach's alpha coefficient was also calculated separately for patients with dcSSc. Items were removed from the HAMIS test one by one, to obtain a test with fewer items while maintaining an α value of ≥ 0.7 . Finger flexion, finger extension, and finger abduction were found to be the most representative items of the original HAMIS test in all groups (Table 2). However, in the dcSSc groups, items for the wrist were also found to be representative: the item for supination in all 3 groups and the item for dorsal extension in 2 of the groups (Table 2). Based on the results of the item reduction analysis and the intention of including items for both the fingers and wrists, an mHAMIS test was created including finger flexion, finger extension, finger abduction, and dorsal extension with a total score ranging from 0 to 12 in each hand (Appendix 1).

The internal consistency of the mHAMIS test in Groups 1–3 was 0.78, 0.83, and 0.73, respectively.

Construct validity of the mHAMIS test. The correlations between the mHAMIS score and the hand skin score and total mRSS were moderate in Groups 1 and 2, and low in Group 3 (Table 3). The correlations between the original HAMIS test and the mHAMIS test (r_s) varied between 0.92 and 0.94. The mHAMIS test discriminated significantly between lcSSc and dcSSc in the total study group ($p = 0.001$), and in Group 1 ($p = 0.034$) and Group 2 ($p = 0.003$). The median mHAMIS score in the total study group was 3 (IQR 1–6) for the patients with lcSSc and 7 (IQR 2.5–12) for the patients with dcSSc. The median mHAMIS score in Group 1 was 4 (IQR 2–7) for the patients with lcSSc and 8 (IQR 5–12.5) for the patients with dcSSc. In Group 2, the median score was 3 (IQR 1–7) for the patients with lcSSc and 6 (IQR 1–11) for the patients with dcSSc. Further, the mHAMIS score differed between patients with and without ulcers in the total study group ($p = 0.015$). The median mHAMIS score for patients without ulcers was 3 (IQR 1–7) and for patients with ulcers was 5 (IQR 3–12.8). There was also a difference between patients with and without pitting

scars in the total study group; the median mHAMIS score being 5 (IQR 2–8) for patients with pitting scars and 2 (IQR 0–6) for patients without pitting scars ($p = 0.001$).

DISCUSSION

Skin fibrosis is a manifest consequence of SSc and impairs joint motion also in the absence of joint involvement. To evaluate the efficacy of specific therapies, there is a need for instruments that measure fibrotic skin involvement specifically. In our present study, we developed an mHAMIS test having only 4 items that showed the same associations with skin involvement as the original HAMIS test, which has 9 different items. We believe that the mHAMIS test can be valuable in assessing the outcome of therapy aimed at reducing fibrotic skin manifestations. The results regarding construct validity and discrimination indicate that the mHAMIS test fulfills the criteria of the OMERACT filter regarding truth and discrimination. The feasibility is better than that of the original HAMIS test because the equipment needed are only 3 cylinders (5 mm, 15 mm, and 30 mm in diameter), and the time required to perform the test is only a few minutes. The 5 mm cylinder can be an ordinary pencil, and the 15 mm and 30 mm cylinders can be made of doweling or plastic piping used for electricity or water installation.

An incidental finding in our study was that the mobility of the right hand was significantly more impaired than that of the left hand, and we therefore calculated Cronbach's alpha coefficient separately for the right and left hands. Unfortunately, we did not record which hand was dominant. About 16% of the inhabitants of Sweden are left-handed, and it is reasonable to assume that the proportion was similar in our study. The finding that finger flexion, finger extension, and thumb abduction were more impaired in the right hand in Group 1 could be explained by the higher skin score in the right hand. Further, it is reasonable to assume that the skin involvement in the first stage of SSc results in skin tightness, especially on the fingers, affecting both finger flexion and extension. The mHAMIS test was developed




Figure 1. Distribution of HAMIS scores in the right hand in Groups A–C: (A) 0–3 years after disease onset, (B) 3.1–5 years after disease onset, and (C) 5.1–9 years after disease onset. Legend represents HAMIS scores. HAMIS: hand mobility in scleroderma.

based on Cronbach’s alpha coefficient, combined with clinical experience showing that skin tightness affects mobility. To make the test more feasible in clinical trials, our

aim was also to minimize the amount of equipment required while retaining the items that involve movements related to the skin score measure area. Regarding the items for the wrist,

Table 2. Cronbach's alpha coefficient for the original HAMIS test and the 4 most representative items in the right and left hands in each group and in the dcSSc subgroups.

Characteristics	Group 1, 0–3 Yrs	Group 2, 3.1–5 Yrs	Group 3, 5.1–9 Yrs
Cronbach's alpha in original HAMIS test			
Right hand	0.829	0.878	0.816
Left hand	0.839	0.868	0.801
Item-reduced HAMIS			
Right hand in all patients with lcSSc and dcSSc	Finger flexion, finger extension, thumb abduction, finger abduction	Finger flexion, finger extension, pinch, finger abduction	Finger flexion, finger extension, thumb abduction, pinch
Cronbach's alpha	0.763	0.828	0.773
Left hand in all patients with lcSSc and dcSSc	Finger flexion, finger extension, finger abduction, supination	Finger extension, finger abduction, supination, dorsal extension	Finger flexion, finger extension, thumb abduction, finger abduction
Cronbach's alpha	0.779	0.807	0.759
Right hand in patients with dcSSc	Finger flexion, pinch, finger abduction, volar flexion	Finger extension, pinch, finger abduction, thumb abduction	Finger flexion, finger extension, finger abduction, supination
Cronbach's alpha	0.886	0.914	0.843
Left hand in patients with dcSSc	Finger flexion, pinch, finger abduction, dorsal extension	Finger extension, finger abduction, supination, dorsal extension	Finger extension, finger abduction, supination, pronation
Cronbach's alpha	0.900	0.934	0.921

HAMIS: hand mobility in scleroderma; dcSSc: diffuse cutaneous SSc; lcSSc: limited cutaneous SSc; SSc: systemic sclerosis.

Table 3. Correlations between the original HAMIS test, the mHAMIS test, and skin score in groups with different disease duration. All values are $p = 0.001$.

Characteristics	Total Study Group		Group 1, 0–3 Yrs		Group 2, 3.1–5 Yrs		Group 3, 5.1–9 Yrs	
	HAMIS	mHAMIS	HAMIS	mHAMIS	HAMIS	mHAMIS	HAMIS	mHAMIS
mRSS	0.42	0.39	0.60	0.59	0.54	0.52	0.39	0.39
Hand skin score	0.45	0.43	0.62	0.61	0.64	0.64	0.45	0.44
Skin score, fingers	0.43	0.43	0.48	0.48	0.58	0.57	0.43	0.46
Skin score, hand	0.35	0.31	0.59	0.59	0.57	0.57	0.32	0.32
Skin score, forearm	0.33	0.30	0.52	0.52	0.35	0.36	0.27	0.24

HAMIS: hand mobility in scleroderma; mHAMIS: modified hand mobility in scleroderma; mRSS: modified Rodnan skin score.

dorsal extension was retained, while supination was excluded because this movement is conducted both in the wrist and elbow, and could be the result of articular manifestations.

The mHAMIS test is shorter and easier to perform than the original HAMIS test, but the 2 are not completely interchangeable. The HAMIS test measures the mobility of the fingers and wrist based on the most common movements assessed in a range-of-motion test. This makes the HAMIS test useful when instructing patients in hand exercises and when monitoring changes in hand mobility. The mHAMIS test consists of a subset of items from the original HAMIS test, and is therefore useful as an instrument for screening hand mobility, but is not as valuable as the HAMIS test in instructing patients in hand exercises.

The moderate correlation between the mHAMIS score and mRSS and hand skin score, and its ability to discriminate between lcSSc and dcSSc in the first 3 years after disease onset (Group 1) demonstrate its usefulness in evaluating skin involvement in the early stages of the disease when information is needed concerning appropriate therapy. However, articular and vascular manifestations may also influence hand function and mobility. The mHAMIS test

developed in our study discriminates between individuals with and without ulcers, and therefore we cannot exclude the possibility that vascular manifestations also affect the mHAMIS score. This is in line with studies by Mouthon, *et al*²⁵, who found that patients with ulcers had significantly greater impairment of hand mobility, and Del Rosso, *et al*⁷, who reported that patients with SSc with arthritis or ulcers had higher HAMIS scores than did patients without arthritis or ulcers.

Our study had some potential limitations. Articular involvement was not recorded, and we cannot exclude the possibility that arthritis may have influenced the HAMIS score, and therefore also the mHAMIS score. Nevertheless, the convincing correlation between the mHAMIS score and skin involvement indicates that the mHAMIS test is a valid measure of skin involvement. In our study, we recorded the incidence of ulcers and pitting scars because those are features of SSc, and associations have been established between joint contracture and vascular involvement²⁶, and between vascular involvement and skin fibrosis²⁷. Our study was based on data collected during routine clinical care and includes a rather small number of patients with dcSSc.

Therefore, Cronbach's alpha coefficient was also calculated separately for patients with dcSSc.

To obtain as complete assessment of hand function and the efficacy of specific therapies as possible, attempts should be made to include measurements from the different domains of the ICF, specifically the scoring of hand function, as well as self-reported questionnaires that assess activity limitations^{7,13}. Although we have previously demonstrated a significant relationship between the original HAMIS and CHFS scores⁹, these tests are not interchangeable, but rather complement each other. The mHAMIS test provides a measure of hand mobility assessed by health professionals, while the CHFS measures the patient's perception of their ability to perform activities in daily living, which can be influenced by function and by other factors. Both measures are needed to evaluate disease severity and the efficacy of drugs and rehabilitation.

The hands account for only a small proportion of the total area of the body, but are important in many functions in daily life. Because of the correlation between the mHAMIS score and the mRSS score, the mHAMIS score may be a relevant outcome measure in evaluating the fibrotic process in the skin of patients with SSc. However, interventional studies are needed to further investigate the responsiveness of the mHAMIS test.

REFERENCES

1. Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse systemic sclerosis. *Arthritis Rheum* 2000;43:2437-44.
2. Nihtyanova SI, Denton CP. Current approaches to the management of early active diffuse scleroderma skin disease. *Rheum Dis Clin North Am* 2008;34:161-79.
3. Poole JL, Watzlaf VJ, D'amico F. A five-year followup of hand function and activities of daily living in systemic sclerosis (scleroderma). *J Hand Ther* 2004;17:407-11.
4. Clements PJ. Measuring disease activity and severity in scleroderma. *Curr Opin Rheumatol* 1995;7:517-21.
5. Sandqvist G, Eklund M, Åkesson A, Nordenskiöld U. Daily activities and hand function in women with scleroderma. *Scand J Rheumatol* 2004;33:102-7.
6. Bassel M, Hudson M, Taillefer SS, Schier O, Baron M, Thombs BD. Frequency and impact of symptoms experienced by patients with systemic sclerosis: result from a Canadian National Survey. *Rheumatology* 2011;50:762-7.
7. Del Rosso A, Maddali Bongi S, Sigismondi F, Miniati I, Bandinelli F, Matucci-Cerinic M. The Italian version of the hand mobility in scleroderma (HAMIS) test: evidence for its validity and reliability. *Clin Exp Rheumatol* 2010;28:S42-7.
8. Ingegnoli F, Galbiati V, Boracchi P, Comi D, Gualtierotti R, Zeni S, et al. Reliability and validity of the Italian version of the hand functional disability scale in patients with systemic sclerosis. *Clin Rheumatol* 2008;27:742-9.
9. Hesselstrand R, Nilsson JÅ, Sandqvist G. Psychometric properties of the Swedish version of Scleroderma Health Assessment Questionnaire and Cochin Hand Index in patients with systemic sclerosis. *Scand J Rheumatol* 2013;42:317-24.
10. Furst DE. Outcome measures in rheumatologic clinical trials and systemic sclerosis. *Rheumatology* 2008;47:29-30.
11. World Health Organization. International classification of functioning, disability and health (ICF). Geneva: World Health Organization; 2001. [Internet. Accessed August 25, 2014.] Available from: www.who.int/classifications/icf
12. Duruoz MT, Poiraudau S, Fermanian J, Menkes C, Amor B, Dougados M, et al. Development and validation of a rheumatoid Duruoz's Hand Index that assesses functional handicap. *J Rheumatol* 1996;23:1167-72.
13. Brower LM, Poole JL. Reliability and validity of the Duruöz hand index in persons with systemic sclerosis (scleroderma). *Arthritis Rheum* 2004;51:805-9.
14. Rannou F, Poiraudau S, Berezne A, Bauvet T, Le-Guern V, Cabane J, et al. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. *Arthritis Rheum* 2007;57:94-102.
15. Backman C, Mackie H, Harris J. Arthritis hand function test: development of a standardized assessment tool. *Occup Ther J Res* 1991;11:245-56.
16. Sandqvist G, Eklund M. Hand Mobility in Scleroderma (HAMIS): the reliability of a novel hand function test. *Arthritis Care Res* 2000;13:369-74.
17. Poole JL, Gallegos M, O'Linc S. Reliability and validity of the Arthritis Hand Function Test in adults with systemic sclerosis (scleroderma). *Arthritis Care Res* 2000;13:69-73.
18. Sandqvist G, Eklund M. Validity of HAMIS: a test of hand mobility in scleroderma. *Arthritis Care Res* 2000;13:382-7.
19. Sandqvist G, Hesselstrand R, Eberhardt K. A longitudinal follow-up of hand involvement and activities of daily living in early systemic sclerosis. *Scand J Rheumatol* 2009;18:1-7.
20. Maddali-Bongi S, Del Rosso A, Galluccio F, Sigismondi F, Miniati I, Conforti ML, et al. Efficacy of connective tissue massage and MC Mennell joint manipulation in the rehabilitative treatment of the hands in systemic sclerosis. *Clin Rheumatol* 2009;28:1167-73.
21. Maddali-Bongi S, Del Rosso A, Passalacqua M, Miccio S, Matucci Cerinic M. Manual lymph drainage improving upper extremity edema and hand function in patients with systemic sclerosis in edematous phase. *Arthritis Care Res* 2011;63:1134-41.
22. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. *Arthritis Rheum* 1980;23:581-90.
23. Bland JM, Altman DG. Cronbach's alpha. *Br Med J* 1997;314:572.
24. Munro BH. Statistical methods for health care research, 3rd edition. Philadelphia: Lippincott Williams & Wilkins; 1997.
25. Mouthon L, Mestre-Stanislas C, Bérezne A, Rannou F, Guilpain P, Revel M, et al. Impact of digital ulcers on disability and health related quality of life in systemic sclerosis. *Ann Rheum Dis* 2010;69:214-7.
26. Avouac J, Walker U, Tyndall LA, Kahan A, Matucci-Cerinic M, Allanorey Y, and EUSTAR. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database. *J Rheumatol* 2010;37:1488-501.
27. Hanitsch LG, Burmester GR, Witt C, Hunzelmann N, Genth E, Krieg T, et al. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations—an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register. *Rheumatology* 2009;48:70-3.

APPENDIX 1. Modified hand mobility in scleroderma (mHAMIS).

The test equipment consists of standardised cylinders for assessment of finger flexion (5, 15, 30 mm diameter) and finger extension (5, 15 mm diameter).

Finger flexion

- All fingers must be tight to the object. 0
- Can bend fingers 2-5 around a pencil (5 mm diam). 1
- Can bend fingers 2-5 around a piece of cutlery (15 mm diam). 2
- Can bend fingers 2-5 around handlebar (30 mm diam). 3
- Cannot manage the previous item. 3



Finger extension

- All fingers must be tight to the object. 0
- Can feel the table completely with digit 2-5. 1
- Can feel the pencil (5 mm diam) with digit 2-5. 2
- Can feel the piece of cutlery (15 mm diam) with digit 2-5. 3
- Cannot manage the previous item. 3



Finger abduction

- Can spread the fingers and then fold the hands together to the bottom of the fingers. 0
- Can spread the fingers and then fold the hands together to the first phalange. 1
- Can spread the fingers and then fold the hands together to the second phalange. 2
- Cannot manage the previous item. 3



Dorsal extension

- Can hold the palms together and put the wrists against the stomach. 0
- Can hold the palms together and put the thumbs against the throat. 1
- Can hold the palms together and put the thumbs up to the mouth. 2
- Cannot manage the previous item. 3

